In conclusion, our findings discovered that SOCS2-AS1 is a novel anti-cancer lncRNA to inhibit CRC progression through regulating miR-1264/SOCS2 pathway, suggesting that SOCS2-AS1 may be a potential therapeutic target. Here, SOCS2 is linked to colorectal carcinoma.